Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Endometrial Neoplasms 2Breast Neoplasms 2von Hippel-Lindau Disease 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Liposarcoma 1Leiomyosarcoma 1Hormone Receptor Positive Breast Cancer 1Hamartoma Syndrome, Multiple 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1Brain Neoplasms 1Bone Neoplasms 1Autistic Disorder 1Astrocytoma 1Angiomyolipoma 1

Interventions

ribociclib 1pembrolizumab 1futibatinib 1Surgical Procedures, Operative 1Neoadjuvant Therapy 1Histamine H2 Antagonists 1Famotidine 1Everolimus 1Erlotinib Hydrochloride 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leiomyosarcoma × Everolimus × 30 days × Clear all
NCT03114527 2026-05-22

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Fox Chase Cancer Center

Phase 2 Active not recruiting
48 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡